Prothena Corporation plc (NASDAQ:PRTA) Weekly Ratings on May 17, 2018

May 17, 2018 - By Pearl Odom

Prothena Corporation plc (NASDAQ:PRTA) Corporate Logo
Big Money Sentiment decreased to 1.18 in 2017 Q4. It has change of 0.47, from 2017Q3’s 1.65. The ratio worsened due to Prothena Corporation plc positioning: 29 sold and 32 reduced. 28 funds took positions and 44 increased positions. Investors holded 31.24 million in 2017Q3 but now own 31.32 million shares or 0.27% more.
Huntington Fincl Bank holds 0% or 73 shs. Fincl Bank Of America De owns 14,055 shs. Winslow Evans And Crocker owns 210 shs or 0% of their US capital. Meeder Asset Mngmt Incorporated holds 108 shs or 0% of its capital. Architects Inc invested in 0% or 1 shs. Ubs Asset Mgmt Americas has 48 shs. Dekabank Deutsche Girozentrale owns 22,150 shs. Bankshares Of Nova Scotia accumulated 14,000 shs. Alliancebernstein Limited Partnership stated it has 1.01M shs or 0.03% of all its holdings. Sphera Funds Ltd holds 0.9% or 205,000 shs in its capital. 2 were reported by Advisory Ser Net Lc. Sei accumulated 5,030 shs. Minnesota-based Us Retail Bank De has invested 0% in Prothena Corporation plc (NASDAQ:PRTA). Sabby Limited Co accumulated 0.09% or 24,730 shs. Teacher Retirement Sys Of Texas holds 0% in Prothena Corporation plc (NASDAQ:PRTA) or 12,830 shs.

Prothena Corporation plc (NASDAQ:PRTA) Ratings Coverage

Total analysts of 10 have positions in Prothena Corp PLC (NASDAQ:PRTA) as follows: 3 rated it a “Buy”, 0 with “Sell” and 7 with “Hold”. The positive are 30%. Since November 20, 2017 according to StockzIntelligence Inc Prothena Corp PLC has 16 analyst reports. On Monday, April 23 the stock of Prothena Corporation plc (NASDAQ:PRTA) has “Hold” rating given by Oppenheimer. In Monday, November 20 report Wedbush downgraded the stock to “Neutral” rating. On Monday, April 23 RBC Capital Markets downgraded Prothena Corporation plc (NASDAQ:PRTA) to “Hold” rating. On Tuesday, March 20 Cantor Fitzgerald maintained the shares of PRTA in report with “Buy” rating. On Thursday, April 5 the stock of Prothena Corporation plc (NASDAQ:PRTA) has “Overweight” rating given by Barclays Capital. On Wednesday, March 21 Oppenheimer maintained Prothena Corporation plc (NASDAQ:PRTA) with “Buy” rating. On Tuesday, April 24 the firm earned “Buy” rating by Nomura. On Thursday, February 15 the firm has “Buy” rating by Cantor Fitzgerald given. On Monday, April 23 the stock has “In-Line” rating by Evercore. On Tuesday, April 24 the stock of Prothena Corporation plc (NASDAQ:PRTA) earned “Buy” rating by Deutsche Bank. Listed here are Prothena Corporation plc (NASDAQ:PRTA) PTs and latest ratings.

24/04/2018 Broker: Nomura Old Rating: Buy New Rating: Buy Old Target: $87 New Target: $19 Maintain
24/04/2018 Broker: Deutsche Bank Old Rating: Buy New Rating: Buy Old Target: $78 New Target: $16 Maintain
24/04/2018 Broker: BTIG Research Old Rating: Buy New Rating: Neutral Old Target: $77 Downgrade
24/04/2018 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Overweight Old Target: $69 New Target: $14 Maintain
23/04/2018 Broker: Oppenheimer Rating: Hold Downgrade
23/04/2018 Broker: RBC Capital Markets Rating: Hold Downgrade
23/04/2018 Broker: Barclays Capital Rating: Hold Downgrade
23/04/2018 Broker: Jefferies Old Rating: Buy New Rating: Hold Old Target: $100 Downgrade
23/04/2018 Broker: Evercore Old Rating: Outperform New Rating: In-Line Old Target: $76 New Target: $12 Downgrade
05/04/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $70 New Target: $50 Maintain

PRTA is hitting $16.31 during the last trading session, after decreased 0.73%.Currently Prothena Corporation plc is downtrending after 31.00% change in last May 17, 2017. PRTA has also 378,815 shares volume. The stock underperformed the S&P500 by 42.55%.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion.The firm is worth $649.50 million. It is developing antibody product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development.Last it reported negative earnings. The firm has a license, development, and commercialization agreement with F.

For more Prothena Corporation plc (NASDAQ:PRTA) news posted briefly go to: Prnewswire.com, Globenewswire.com, Nasdaq.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “PROTHENA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50000 …” posted on May 16, 2018, “Prothena to Report First Quarter 2018 Financial Results on May 8” on May 01, 2018, “Prothena Reports First Quarter 2018 Financial Results and Provides R&D Update” with a publish date: May 08, 2018, “Prothena: What Now?” and the last “Prothena: A Compelling Bounce Play To At Least $15 And Not Unrealistic Buyout Target” with publication date: April 25, 2018.

Prothena Corporation plc (NASDAQ:PRTA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.